What to Track When Taking GLP-1 Medications Weekly

Six data points per dose. That is the minimum viable log for weekly GLP-1 medications like semaglutide and tirzepatide. Everything else — symptom journals, body metrics, titration notes — is useful context that you layer on once the foundation is solid. Most people who quit tracking do so because they started with too many fields and burned out in three weeks.

This guide covers the fields that matter, the order to add them, and the formats that stay useful over months of weekly dosing.

The Core Fields for Every Weekly Dose

Every time you inject, record these six things before you cap the needle:

That is your entire log entry at its leanest. It takes about fifteen seconds. If you do nothing else, do this — it creates the backbone for every downstream analysis you or your clinician might need.

The date and time fields seem obvious, but they earn their keep during titration. When you bump from 0.25 mg to 0.5 mg of semaglutide and nausea spikes three hours post-dose, the timestamp is what connects the symptom to the dose. Without it, you are reconstructing timelines from memory at your next appointment, and memory is bad at this.

Minimum Viable Log vs. Full Clinical Context

There is a real tension between logging enough to be useful and logging so much that you stop doing it. The answer is progressive disclosure: start lean, stabilize the habit, then expand.

Weeks 1-4: Minimum Viable Log

Stick with the six core fields above plus one binary field:

• Completed on schedule? Yes / No (if no, note delay in hours or reason)

Seven fields. That is it. Your only goal in the first month is to prove to yourself that you can log consistently on dose day. If you skip a week of logging, the system has already failed — and it was not because you lacked a symptom severity scale.

Weeks 5+: Clinical Context Layer

Once weekly logging is automatic, add these fields one at a time, not all at once:

• Symptom severity (0-3 scale, defined below)
• Symptom onset (hours post-dose)
• Appetite note (increased / normal / reduced / absent)
• Hydration note (adequate / low / flagged)
• Supply status (doses remaining, next refill date)

The supply field sounds administrative, but a lapsed prescription is the most common reason for an unplanned gap in GLP-1 therapy. If you track doses remaining, you will never be surprised by an empty pen. For more on handling gaps when they do happen, the missed dose log template covers root-cause tracking and prevention.

Injection Site Tracking and Why It Matters for Weekly GLP-1s

Weekly dosing gives your tissue seven full days of recovery between injections, which is generous. But that recovery only works if you are actually rotating. People who do not track their injection site tend to drift back to the same comfortable spot — usually somewhere on the abdomen — and stay there for months.

The consequence is lipohypertrophy: hardened fatty lumps that form under the skin at overused sites. Lipohypertrophic tissue absorbs medication unpredictably, which means your carefully titrated dose might hit harder one week and barely register the next. For a drug class where steady blood levels drive both efficacy and side effect management, that inconsistency matters.

Your log should capture:

• Body region: Abdomen, thigh, or upper arm
• Specific zone: Which quadrant within the region (upper left abdomen, lower right abdomen, etc.)
• Side: Left or right

A visual body map — where you tap the actual location on a diagram rather than writing "left abdomen" — is significantly better than text for this. Text entries are ambiguous across weeks. A dot on a map is not.

For the full rotation system, including the quadrant method and a monthly self-check protocol for catching lipohypertrophy early, see the injection site rotation guide.

Symptom Logging That Stays Useful

Free-text symptom notes are almost useless after about four weeks. "Felt kind of off" and "stomach was weird" do not help you spot patterns, and they definitely do not help your clinician make dosing decisions. Structured entries do.

The Four-Field Symptom Format

For each symptom worth noting, capture:

• Symptom: Name it specifically (nausea, not "stomach stuff")
• Severity: 0-3 scale
• Onset: Hours after dose
• Duration: Hours or days
• Impact: What it changed about your day (optional but valuable)

The severity scale needs to be consistent and defined up front, or it drifts:

An example entry:

Symptom: Nausea | Severity: 1 | Onset: 2h post-dose | Duration: 4h | Impact: Ate smaller dinner, no missed activities

That is one line. It takes twenty seconds to write. And when you have eight weeks of entries in this format, patterns jump out: nausea always starting 2-3 hours post-dose, always resolving by evening, severity dropping from 2 to 1 after week three at the current dose. That is the kind of signal your clinician can act on.

When to Log Symptoms

You do not need to log every day. The practical schedule:

• Dose day: Log within 1 hour of injecting (baseline), then again before bed
• Day after dose: One entry, end of day — this is when most GLP-1 side effects peak
• Days 3-7: Log only if something deviates from your normal pattern

This keeps the burden low while capturing the window where side effects actually cluster.

GI Side Effects: The Ones You Will Probably Track Most

GLP-1 receptor agonists slow gastric emptying. That is part of how they work, and it is also why gastrointestinal side effects are the most commonly reported adverse events for both semaglutide and tirzepatide. Your log should be set up to capture them efficiently.

The big three:

Nausea. The most common side effect during titration. Typically peaks in the first 48 hours after a dose, improves over subsequent weeks at the same dose level, and often returns briefly after each dose escalation. Track onset, duration, and severity using the 0-3 scale. Also note whether it correlates with meal timing — many people find that eating a large meal within a few hours of dosing makes nausea worse.

Constipation. Less dramatic than nausea but more persistent for some people. Track using a simple daily yes/no field or note the number of days since last bowel movement. If constipation is a recurring issue, add a hydration and fiber intake note — these are the two variables you can actually adjust.

Appetite changes. This one is both a side effect and a therapeutic goal, which makes it worth tracking carefully. A simple four-point scale works: increased / normal / reduced / absent. Note it daily during the first two weeks at a new dose, then weekly once it stabilizes. A sudden shift — appetite returning to baseline after weeks of suppression, or appetite disappearing entirely — is a signal worth flagging for your provider.

Less common but worth noting if they appear: diarrhea, acid reflux, bloating, and injection site reactions. These do not need dedicated fields unless they become recurring. A free-text "other notes" field handles them fine.

Body Metrics Worth Tracking (and the Ones That Are Not)

Weight is the obvious metric for people taking GLP-1s for weight management, and it is worth tracking — but with guardrails.

Weight: Trend, Not Data Points

Weigh yourself once per week, same day, same time, same conditions (morning, after bathroom, before eating). Do not weigh daily. Daily weight fluctuates by 1-3 pounds from water, food volume, and sodium intake. Those fluctuations are noise, and they generate anxiety that undermines adherence.

What you want is a four-week trend line. Is the overall direction down, flat, or up? That is the signal. Individual weekly readings are just inputs to that trend.

Log it as: Weight: 187.4 lbs (4-week trend: -3.2 lbs)

Beyond the Scale

Three subjective metrics add real context and take almost no effort to log:

• Energy level: 1-5 scale, once daily or on dose day. GLP-1s can affect energy, especially during caloric deficit. A sustained drop in energy at a given dose is worth discussing with your provider.
• Appetite: Already covered above. Dual-purpose — it is both a side effect metric and an efficacy indicator.
• Mood: Simple 1-5 or a three-word note ("steady," "irritable," "good"). Caloric restriction affects mood. If your mood consistently tanks at a certain dose, that is data.

What is not worth tracking routinely: blood glucose (unless you are diabetic or pre-diabetic and your provider has asked for it), ketone levels, detailed macronutrient intake, sleep latency. These are fine for specific clinical situations, but adding them to a general GLP-1 log increases friction without proportional benefit for most users.

Titration Tracking: Logging Dose Escalations

Titration is where tracking pays its biggest dividends. Both semaglutide and tirzepatide follow stepped dose escalation protocols — you start low, increase at defined intervals, and monitor tolerance at each level. Your log is what tells you whether you are tolerating each step.

What to Record at Each Dose Change

When you escalate:

• New dose and date of change
• Previous dose and duration at that dose (weeks)
• Reason for escalation (scheduled protocol step, provider-directed, self-initiated)
• Baseline symptom status at the old dose before switching

Then for the next two weeks at the new dose, log symptoms with extra attention. This is when the structured four-field format matters most. You are building a before/after comparison that answers a specific question: did this dose increase cause new or worsened side effects, and if so, how severe and how long did they last?

A Practical Titration Table

That table is worth more in a clinical conversation than ten minutes of verbal recollection. It shows your provider exactly what happened at each step, with severity quantified and tolerability assessed. If you need to step back down or hold at a dose longer, the reasoning is documented.

The Weekly Summary Format for Clinician Conversations

Raw log entries are for you. Summaries are for your clinician. Before any appointment or check-in, distill your recent logs into a five-line format:

1. Doses completed vs. planned (e.g., 4/4 over the last month)
2. Delayed or missed doses and reason (e.g., 1 delayed 6 hours — travel)
3. Recurring symptoms with trend (e.g., nausea improving, was 2/3, now 1/3)
4. Weight trend (e.g., -2.8 lbs over 4 weeks)
5. Top 1-2 questions (e.g., "Ready to escalate from 0.5 mg?" or "Constipation persistent — options?")

This format respects your provider's time, demonstrates that you are engaged in your treatment, and moves the conversation directly to decisions rather than data collection. Providers who see patients on GLP-1s report that structured summaries significantly improve visit efficiency — they spend less time asking questions and more time adjusting treatment.

If you are combining oral and injectable medications, roll both into a single summary rather than maintaining separate reports.

Common Logging Mistakes and How to Avoid Them

After building a tracking app and talking to hundreds of GLP-1 users, the same failure modes come up repeatedly.

Starting with too many fields. The most common mistake by far. You download a template with 15 fields, fill it out meticulously for two weeks, and then stop entirely because it feels like homework. Start with six fields. Add more only after the habit is stable.

Logging dose but not site. Dose adherence gets all the attention, but site rotation is the field most likely to prevent a long-term problem. If you track one thing beyond the basics, make it the injection location.

Vague symptom notes. "Felt bad" is not actionable. "Nausea, 2/3 severity, onset 3h post-dose, lasted 5h" is. The difference is thirty seconds of effort and the four-field format described above.

Tracking weight daily instead of weekly. Daily weigh-ins create noise that obscures the trend. They also create emotional volatility that can undermine your commitment to the protocol. Weekly, same conditions, trend line over four weeks.

Not logging dose escalation dates. When you increase your dose without recording when, you lose the ability to correlate new symptoms with the change. Every dose change is a significant event — treat it like one in your log.

Keeping the log in a format that is hard to review. Scattered notes across multiple apps, texts to yourself, and paper scraps are not a log. They are a scavenger hunt. One system, one location, consistent format. Our best GLP-1 tracker app guide compares six apps purpose-built for this kind of weekly injectable logging.

Forgetting to prepare summaries for appointments. Your raw log is not what your clinician needs. The five-line weekly summary converts data into decisions. Prepare it before every visit.

FAQ

What is the most important GLP-1 data point to track? Date, time, medication name, dose, injection site, and side. These six fields form the minimum viable log. Without them, your records cannot support titration decisions or clinician conversations.

Should I track symptoms every day or just on dose day? Brief daily notes are ideal during the first two days after each dose, when GI side effects are most likely. After those 48 hours, a quick end-of-day note on appetite and energy is enough unless something changes.

How do I share my GLP-1 log with my doctor? Prepare a weekly summary with doses completed versus planned, recurring symptoms with severity, weight trend direction, and one or two specific questions. A structured summary is far more useful to a clinician than a raw data dump.

Done Dose was built for weekly injectable tracking. Log your dose with a single tap, mark your injection site on a visual body map, track symptoms with structured severity scales, and generate summaries you can share with your provider. No spreadsheets, no guessing where you injected last week. Start tracking at donedose.com